Keywords: venture capital, health care, biomarkers
Summary:We will talk about one of Blackhorn Venture Capital's ongoing success stories. Cytovale is a team of biologists, data scientists, and engineers developing mechanical biomarkers to improve human health. Their novel microfluidic platform allows us to probe individual cells to quantify the mechanical signatures of disease. Cytovale technology is being applied first to sepsis, a condition whose early detection dramatically improves patient outcomes and reduces treatment cost. Reflecting our technology/biology hybrid company, at Cytovale's HQ, the data team sits across from a wet lab, and the biologists handle python as well as pipettes. Our broad culture is built on the belief that close collaboration across teams helps us move fast to bring health insights to patients and their healthcare providers while creating value for our investors.